Benefits
Shifts a Urinary Estrogen Metabolite Marker
In a placebo-controlled dose-ranging trial in 60 women at increased breast cancer risk, 4 weeks of I3C raised the urinary 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio at 300 and 400 mg/day, while 50 to 200 mg/day did the same as placebo. A phase I study in 17 women found a 66 percent rise in the same ratio, with no further gain going from 400 to 800 mg/day. This ratio is a laboratory marker of how the body processes estrogen. No trial has shown that moving it changes how a person feels, and in that phase I study serum estradiol, progesterone, LH, FSH and SHBG did not change.
Studied Only as a Hospital Add-On After Surgery, Not a Self-Care Use
This research was done in hospital patients, not in supplement users. In a prospective open-label study with no control group, 33 patients taking 200 mg twice daily after surgery were followed for a mean of 4.8 years: 11 needed no further surgery, 10 needed surgery less often, and 12 had no response, while a further 12 patients were lost to follow-up and could not be counted. A separate observational series in 87 Russian children reported lasting remission in 28.7 percent and no apparent effect in 29.9 percent. Neither study had a placebo group, so the natural course of the condition cannot be separated out. The surgical care these patients received is the treatment; I3C was added on top of it.
Studied Only in Women Already Under Gynecologic Care
One placebo-controlled trial randomized 30 women with biopsy-confirmed high-grade cervical lesions to placebo, 200 mg/day or 400 mg/day for 12 weeks. Complete regression on the 12-week biopsy occurred in 0 of 10 on placebo, 4 of 8 on 200 mg and 4 of 9 on 400 mg. That is one small trial in monitored patients, and it has not been repeated. A later randomized study in 12 women with high-grade vulvar lesions found itch, pain and appearance improved, but the biopsy grade did not improve at 6 months. Screening and the care a gynecologist prescribes are what manage these findings.
Liver Enzyme Induction, Which Cuts Both Ways
This has been measured in people, once. In 17 women taking 800 mg/day, CYP1A2 activity rose about 4-fold on a caffeine probe and lymphocyte glutathione S-transferase activity rose 69 percent. Speeding up those enzymes also speeds the clearance of medicines that depend on them, which is why the interaction list below matters: the same induction described here as detoxification is the reason I3C can lower drug levels. No trial has shown that this enzyme shift improves health in someone who is not taking a drug.
Antioxidant and Anti-Inflammatory Effects: Cell Studies Only
These effects come from cell culture and animal work, including NF-kB signalling in cultured cells. No trial has measured an antioxidant or inflammatory outcome in people taking I3C itself. The one human study in this area that lowered a marker of oxidative stress fed 218 g a day of broccoli and other brassica vegetables, not an I3C supplement.
Mechanism of action
Conversion to DIM and Other Active Metabolites
I3C itself is largely converted in the acidic stomach environment to DIM (3,3'-diindolylmethane), ascorbigen, and indolo[3,2-b]carbazole (ICZ). I3C is essentially a 'pro-drug' for these active metabolites — DIM is the most studied.
CYP1A1/CYP1A2 Induction (Same as DIM)
Promotes estrogen 2-hydroxylation pathway. Same fundamental mechanism as DIM since I3C converts to DIM.
Aryl Hydrocarbon Receptor (AhR) Activation
ICZ (indolocarbazole) — an I3C metabolite — is one of the most potent natural AhR ligands. Activates extensive xenobiotic metabolism gene expression.
Anti-HPV Effects
Activity against HPV-infected cells has been shown in cell culture. This is a laboratory observation, and no study has shown that taking I3C clears HPV in a person.
Clinical trials
Placebo-controlled, double-blind dose-ranging trial of I3C at 50, 100, 200, 300 or 400 mg/day for 4 weeks in 60 women at increased breast cancer risk, 57 of whom completed, measuring urinary estrogen metabolites.
Women at increased breast cancer risk, mean age 47, range 22 to 74.
The urinary 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio rose in the 300 and 400 mg/day groups, while 50 to 200 mg/day behaved like placebo. The ratio is a surrogate biomarker, and no clinical outcome was measured in this trial.
Prospective open-label study with no placebo and no control group: I3C at 200 mg twice daily in 33 patients followed for a mean of 4.8 years after surgical removal of papillomas.
Adults and children treated at a hospital voice centre after surgery, including 9 paediatric patients.
11 of 33 patients needed no further surgery while taking I3C, 10 needed surgery less often, and 12 had no response; a further 12 patients were lost to follow-up. Of 9 children, 1 responded completely, 3 partly and 5 not at all. With no control group there is no way to separate the effect of I3C from the natural course of the condition.